{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:32:45Z","timestamp":1788535965333,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jfma.2020.08.010","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T17:46:40Z","timestamp":1598032000000},"page":"1593-1600","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir\/pibrentasvir therapy"],"prefix":"10.1016","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4949-393X","authenticated-orcid":false,"given":"Wei-Ming","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Liang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shui-Yi","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Heng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Te-Sheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wei","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Yu","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen Nan","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Hung","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Nan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1 Suppl","key":"10.1016\/j.jfma.2020.08.010_bib1","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","article-title":"Natural history of hepatitis C","volume":"61","author":"Westbrook","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.08.010_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jfma.2015.06.012","article-title":"Hepatitis C virus infection in Taiwan: past, present, and future","volume":"115","author":"Kao","year":"2016","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2020.08.010_bib3","doi-asserted-by":"crossref","first-page":"1 42","DOI":"10.1053\/j.gastro.2016.09.009","article-title":"Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications","volume":"152","author":"Nahon","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2020.08.010_bib4","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2020.08.010_bib5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2020.08.010_bib6","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s40262-019-00774-0","article-title":"Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations: a 2019 update","volume":"58","author":"Smolders","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jfma.2020.08.010_bib7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3350\/cmh.2020.0018","article-title":"Unmet needs of chronic hepatitis C in the era of directacting antiviral therapy","volume":"26","author":"Huang","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jfma.2020.08.010_bib8","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2020.08.010_bib9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","article-title":"Glecaprevir\/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial","volume":"72","author":"Brown","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.08.010_bib10","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/hep.29510","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection","volume":"67","author":"Toyoda","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.08.010_bib11","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jfma.2020.08.010_bib12","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2020.08.010_bib13","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jvh.13265","article-title":"Glecaprevir\/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment","volume":"27","author":"Liu","year":"2020","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2020.08.010_bib14","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000350738","article-title":"Role of viral genotypes and hepatitis B viral mutants in the risk of hepatocellular carcinoma associated with hepatitis B and C dual infection","volume":"56","author":"Hung","year":"2013","journal-title":"Intervirology"},{"key":"10.1016\/j.jfma.2020.08.010_bib15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/cld.442","article-title":"New treatments for HCV: perspective from Asia","volume":"5","author":"Yu","year":"2015","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jfma.2020.08.010_bib16","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jfma.2019.06.014","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir in Asian patients with chronic hepatitis C","volume":"118","author":"Hsu","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2020.08.010_bib17","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/liv.14295","article-title":"Glecaprevir\/pibrentasvir for patients with chronic hepatitis C virus infection: real-world effectiveness and safety in Taiwan","volume":"40","author":"Liu","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2020.08.010_bib18","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2020.08.010_bib19","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1111\/j.1365-2893.2011.01537.x","article-title":"Performance of acoustic radiation force impulse imaging for the staging of liver fibrosis: a pooled meta-analysis","volume":"19","author":"Friedrich-Rust","year":"2012","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2020.08.010_bib20","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/apt.15222","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry","volume":"49","author":"Berg","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2020.08.010_bib21","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/jgh.14874","article-title":"Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection","volume":"35","author":"Toyoda","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2020.08.010_bib22","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2018.11.011","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir in 723 patients with chronic hepatitis C","volume":"70","author":"D'Ambrosio","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.08.010_bib23","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/jvh.13170","article-title":"Evaluation of 8-week glecaprevir\/pibrentasvir treatment in direct-acting antiviral-na\u00efve noncirrhotic HCV genotype 1 and 2 infected patients in a real-world setting in Japan","volume":"26","author":"Ikeda","year":"2019","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2020.08.010_bib24","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/jgh.13747","article-title":"Hepatitis C treatment from \"response-guided\" to \"resource-guided\" therapy in the transition era from interferon-containing to interferon-free regimens","volume":"32","author":"Yu","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2020.08.010_bib25","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/jcph.1262","article-title":"Exposure-response (efficacy) analysis of daclatasvir and asunaprevir in Japanese patients with hepatitis C virus infection","volume":"58","author":"Ueno","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jfma.2020.08.010_bib26","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jfma.2018.11.007","article-title":"Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions","volume":"118","author":"Yu","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2020.08.010_bib27","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2020.08.010_bib28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2020.08.010_bib29","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/apt.15633","article-title":"Systematic review with meta-analysis: impact of baseline resistance-associated substitutions on the efficacy of glecaprevir\/pibrentasvir among chronic hepatitis C patients","volume":"51","author":"Singh","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2020.08.010_bib30","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1038\/s41598-019-43554-3","article-title":"Real-world safety and efficacy of paritaprevir\/ritonavir\/ombitasvir plus dasabuvir\u00b1ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis","volume":"9","author":"Chen","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2020.08.010_bib31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s005350300025","article-title":"Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis","volume":"38","author":"Hung","year":"2003","journal-title":"J Gastroenterol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664620303843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664620303843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:43:10Z","timestamp":1760539390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664620303843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0929664620303843"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2020.08.010","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir\/pibrentasvir therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2020.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}